This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only 9,27 € per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
The datasets generated and analyzed during the current study are not publicly available due to containing identifiable patient information but are available in a deidentified fashion from the corresponding author on reasonable request.
Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014;28:31–40.
Mohty M, Duarte RF, Croockewit S, Hübel K, Kvalheim G, Russekk N. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia. 2011;25:1–6.
Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20:295–308.
Basak GW, Wiktor-Jedrzejczak W, Apperley JF, Douglas KW, Gabriel IH, Geraldes C, et al. Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. Bone Marrow Transplant. 2012;47:1003–5.
Andhavarapu S, Roy V, Zubair A. Effect of body mass index on mobilizing efficacy of plerixafor in patients undergoing autologous stem cell collection: a retrospective study. Biol Blood Marrow Transplant. 2013;19 Suppl 1:S179.
DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:4767–73.
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–6.
World Health Organization Fact Sheet: Obesity and Overweight. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 26 Mar 2015.
Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, et al. Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant. 2012;47:1403–8.
Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20:1262–73.
Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF, et al. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant. 2003;31:861–4.
Topcuoglu P, Soydan EA, Ekiz F, Ayyildiz E, Dalva K, Ozcan M, et al. How to calculate the quantity of CD34+ cells infused? A single center cohort study based on actual, ideal or adjusted ideal body weight. Transfus Apher Sci. 2007;36:275–80.
Maclean PS, Parker AN, McQuaker IG, Clark AD, Farrell E, Douglas KW. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplant. 2007;40:665–9.
Hicks C, Trickett A, Kwan YL, Ramanathan S. The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation. Ann Hematol. 2012;91:1795–801.
SW acknowledges the WVCTSI support from the National Institute of General Medical Sciences grant U54GM104942.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Yingling, S.K., Gonzalez, R.M., Dillaman, M. et al. Impact of body mass index (BMI) on the efficacy of plerixafor for hematopoietic progenitor cell (HPC) mobilization. Bone Marrow Transplant (2022). https://doi.org/10.1038/s41409-022-01685-8